Top Page
EKF Diagnostics Holdings
(LSE:EKF)
EKF Diagnostics Holdings (EKF) vs. iShares MSCI United Kingdom ETF (EWC)
EKF Diagnostics Holdings Business Overview & Revenue Model
EKF Diagnostics Holdings Earnings Call Summary
EKF Diagnostics Holdings Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 50.22M | 50.19M | 52.61M | 66.64M | 81.84M | 65.26M |
| Gross Profit | 25.00M | 21.48M | 23.86M | 24.04M | 39.37M | 37.42M |
| EBITDA | 11.47M | 11.16M | 7.68M | -2.18M | 27.39M | 20.04M |
| Net Income | 6.12M | 6.24M | 2.35M | -10.10M | 15.85M | 11.11M |
Balance Sheet | ||||||
| Total Assets | 82.43M | 81.75M | 80.85M | 89.29M | 115.12M | 101.27M |
| Cash, Cash Equivalents and Short-Term Investments | 16.62M | 13.01M | 6.02M | 11.58M | 20.34M | 21.91M |
| Total Debt | 1.12M | 1.32M | 4.10M | 1.55M | 3.47M | 1.96M |
| Total Liabilities | 9.55M | 8.53M | 12.63M | 14.77M | 20.38M | 23.07M |
| Stockholders Equity | 71.73M | 72.33M | 67.12M | 73.35M | 94.12M | 77.65M |
Cash Flow | ||||||
| Free Cash Flow | 9.47M | 11.41M | -664.00K | 3.86M | 4.59M | 11.16M |
| Operating Cash Flow | 10.71M | 13.66M | 6.31M | 9.69M | 10.24M | 13.81M |
| Investing Cash Flow | -1.84M | -2.66M | -5.64M | -8.93M | -5.48M | 1.34M |
| Financing Cash Flow | -1.44M | -4.08M | -3.65M | -11.04M | -6.16M | -5.21M |
EKF Diagnostics Holdings Technical Analysis
EKF Diagnostics Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | £110.44M | 19.26 | 8.71% | ― | -1.43% | 28.57% | |
58 Neutral | £7.91M | 1,275.00 | 0.08% | ― | 87.72% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | £18.16M | -1.59 | -51.63% | ― | 31.78% | 10.27% | |
41 Neutral | £46.40M | -1.88 | ― | ― | ― | ― | |
40 Underperform | £41.73M | -12.90 | ― | ― | 1557.07% | 24.70% |
EKF Diagnostics Holdings Corporate Events
EKF Diagnostics Holdings plc has announced the purchase of 141,000 of its ordinary shares at a weighted average price of 25.8 pence per share, which will be held in treasury. This share buyback is part of a strategic move to manage the company’s share capital and maintain the aggregate indirect beneficial interest of Mr. Mills, a non-executive director, at approximately the same level, ensuring it does not exceed 30% of the total voting rights. The transaction reflects EKF’s ongoing efforts to optimize its capital structure and maintain shareholder value.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced an extension to its share buyback program, intending to purchase additional ordinary shares worth approximately £1.0 million. This move follows previous buyback extensions and aims to hold the shares in treasury. The company recently acquired 1,844,000 ordinary shares at a weighted average price of 25.8 pence per share. This buyback is part of a strategy to manage the company’s share capital and maintain shareholder value, with implications for the company’s market positioning and stakeholder interests, particularly in maintaining the indirect beneficial interest of Mr. Mills, a significant shareholder.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced that its total issued share capital consists of 449,093,790 ordinary shares, with 7,330,636 shares held in treasury, resulting in 441,763,154 shares carrying voting rights. This information is crucial for shareholders to determine their interest in the company’s share capital under the Financial Conduct Authority’s Disclosure and Transparency Rules.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has executed a share buyback, acquiring 309,384 ordinary shares at a weighted average price of 26.6 pence per share, which will be held in treasury. This move is part of a strategic decision to manage its share capital and maintain the aggregate indirect beneficial interest of a key stakeholder, Mr. Mills, at approximately the same level, ensuring it does not exceed 30% of the total voting rights. The transaction reflects EKF’s ongoing efforts to optimize shareholder value and manage its equity structure effectively, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced a share buyback, purchasing 283,000 ordinary shares at an average price of 26 pence per share, which will be held in treasury. This transaction, including the acquisition of shares from Harwood as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensures that Mr. Mills’ indirect beneficial interest remains stable and does not exceed 30% of the company’s total voting rights. This strategic move is part of EKF’s efforts to manage its share capital and maintain shareholder value.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced a share buyback, purchasing 1,063,000 of its ordinary shares at a weighted average price of 26 pence per share, which will be held in treasury. This transaction, part of a strategic move to manage the company’s share capital, involves acquiring shares from Harwood as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring Mr. Mills’ beneficial interest remains stable. The buyback reflects EKF’s efforts to optimize its capital structure and maintain shareholder value, potentially impacting its market position and stakeholder interests.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced the repurchase of 410,344 of its ordinary shares at a weighted average price of 25.8926 pence per share, which will be held in treasury. This buyback is part of a strategy to manage the company’s share capital and maintain the indirect beneficial interest of key stakeholders, such as Mr. Mills, who retains an aggregate indirect interest of 130,756,000 shares. The transaction reflects EKF’s ongoing efforts to optimize its capital structure and maintain shareholder value.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced the repurchase of 414,793 of its ordinary shares, which will be held in treasury. This buyback is part of a strategy to maintain shareholder value and manage the company’s capital structure. The transaction involved acquiring shares from Harwood, the investment manager for Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring that Mr. Mills’ indirect beneficial interest remains stable. The buyback reflects EKF’s commitment to optimizing its financial operations and maintaining a balanced approach to its shareholding structure.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced the repurchase of 429,593 ordinary shares at an average price of 26 pence per share, which will be held in treasury. This move is part of a strategic buyback plan to manage share capital and maintain shareholder value, with implications for voting rights and shareholding structures, particularly concerning the interests of Mr. Mills, a significant stakeholder.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced a share buyback, purchasing 400,156 of its ordinary shares at a price of 28 pence each, which will be held in treasury. This transaction, part of a strategic move to manage share capital, involves the acquisition of shares from Harwood, the investment manager for Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring Mr. Mills’ indirect beneficial interest remains stable. The buyback reflects EKF’s commitment to optimizing its capital structure and potentially enhancing shareholder value.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced the purchase of 445,321 of its ordinary shares at a weighted average price of 28 pence per share, which will be held in treasury. This buyback includes a transaction involving the acquisition of shares from Harwood, the investment manager for Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, to maintain Mr. Mills’ indirect beneficial interest in the company. The share buyback impacts the company’s total voting rights, with 445,073,424 shares now carrying voting rights, and reflects strategic financial management to optimize shareholder value.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the purchase of 919,331 of its ordinary shares at an average price of 28 pence per share, which will be held in treasury. The company also extended its share buyback program to include additional purchases of up to £1.0 million. This move is part of a strategy to manage the company’s capital structure and potentially enhance shareholder value. The buyback includes shares acquired from Harwood as an investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring that Mr. Mills’ indirect beneficial interest remains stable. Following the buyback, the total number of ordinary shares carrying voting rights is 445,518,745.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced a share buyback, purchasing 929,169 ordinary shares at a weighted average price of 27.5269 pence per share, which will be held in treasury. This transaction includes a notable acquisition of shares from Harwood, acting as an investment manager for Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring that Mr. Mills’ aggregate indirect interest remains stable. The buyback impacts the company’s total voting rights, now consisting of 446,438,076 shares, and reflects a strategic move to manage shareholder interests and market positioning.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the buyback of 929,169 of its ordinary shares, which will be held in treasury. This move is part of a strategic effort to manage its share capital and maintain the indirect beneficial interest of Mr. Mills, a non-executive director, at a stable level. The transaction involved acquiring shares from Harwood, acting as an investment manager for Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC. The buyback reflects EKF’s ongoing commitment to optimizing shareholder value and maintaining a balanced shareholding structure.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced a share buyback, purchasing 1,017,352 ordinary shares at a weighted average price of 28 pence per share, which will be held in treasury. This move is part of a strategic effort to manage the company’s share capital and maintain the aggregate indirect beneficial interest of Mr. Mills, a non-executive director, at approximately the same level, ensuring it does not exceed 30% of the total voting rights in the company. The transaction involved acquiring shares from Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, facilitated by Harwood, the investment manager.
The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.35 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the repurchase of 709,193 of its ordinary shares at a price of 28 pence per share, which will be held in treasury. This buyback is part of a strategic move to manage the company’s share capital and maintain shareholder value. The transaction includes the acquisition of shares from Harwood as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring that Mr. Mills’ indirect beneficial interest remains stable and does not exceed 30% of the total voting rights. This move could impact the company’s market positioning by potentially increasing shareholder confidence and stabilizing the share price.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £32.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings’ recent earnings call conveyed a generally positive sentiment, highlighting notable revenue and profit growth, increased production capacity, and successful new contracts. Despite facing challenges in the APAC region and some market constraints affecting their share buyback program, the company remains optimistic. The positives, including significant production increases and strategic growth plans, appear to outweigh the negatives.
EKF Diagnostics Holdings plc has announced the implementation of a Long Term Incentive Plan (LTIP) for its senior executives, with a specific award granted to CEO Gavin Jones. The LTIP is designed to align executive performance with shareholder value creation, with vesting conditions based on the growth of Adjusted EBITDA per share over a three-year period. This move reflects the company’s commitment to incentivizing its leadership while potentially enhancing its market position and stakeholder confidence.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £31.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc reported record analyzer sales and improved earnings for the first half of 2025, with gross margins rising to 50.2% and a 16.1% increase in pre-tax profit. The company is on track to meet full-year revenue and adjusted EBITDA growth expectations, supported by strong performances in Hematology and β-HB product lines. The strategic development plan is yielding results, with increased production capacity and a focus on high-margin products driving profitability. The company also completed a share buyback and canceled a loan facility due to strong cash generation, indicating a robust financial position.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £31.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc will announce its interim results for the first half of 2025 on 16 September and will host a live online presentation for investors on the same day. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £31.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the signing of three new contracts in the Hematology point-of-care testing sector, valued at approximately €4.65 million. These contracts, secured by EKF’s distribution partners in Latin America and Africa, include a significant return to the Peruvian market and the company’s first sales in Uganda. To meet the rising demand, EKF plans to increase its production capacity by 30% at its Barleben site as part of its five-year strategic development plan. This expansion reinforces the company’s confidence in achieving its revenue and adjusted EBITDA targets for FY 2025, aligning with market expectations. The continued global expansion of EKF’s Hematology analyzer footprint is expected to drive future growth and higher margin revenue through consumable pull-through.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £29.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the signing of three new contracts in the Hematology point-of-care testing sector, valued at approximately €4.65 million. These contracts, secured by distribution partners in Latin America and Africa, mark significant sales growth in Peru and new market entry in Uganda. To meet rising demand, EKF is increasing its production capacity by 30% at its Barleben site as part of its five-year strategic development plan. This expansion is expected to drive revenue and adjusted EBITDA growth in line with market expectations, reinforcing the company’s confidence in its strategic focus on Hemoglobin testing as a key growth area.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £29.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.